Equity Profile

CNTA

Centessa Pharmaceuticals plc

Health CareBiotechnology$6.2B

Aug11Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Centessa Pharmaceuticals plc is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, it plays a crucial role in advancing medical treatments, particularly in areas where there are unmet needs.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales, which is vital for sustaining operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of -$0.52, which was worse than the expected -$0.38, resulting in a 36.84% negative surprise. The stock reacted with a slight decline of 0.08% the following day.

Management Promises & Guidance

Focus on advancing key clinical programs.
Commitment to managing costs effectively.
Plans to provide more transparency on future revenue expectations.

Expectations

Wall Street Expectations

Overall expectations for Centessa's upcoming earnings are cautious, especially given the recent earnings miss and lack of analyst estimates. Investors are looking for signs of improvement in clinical trial progress and financial performance.

Bull Case

If Centessa can demonstrate significant advancements in its clinical trials and better-than-expected EPS, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company reports another earnings miss or provides disappointing updates on clinical trials, it could further erode investor confidence and lead to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on ongoing clinical trials?

Investors will closely watch for any progress or setbacks in clinical trials, as these can significantly influence the company's future prospects.

How does management plan to address the recent earnings misses?

Understanding management's strategy to improve financial performance is crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa to recover from its recent earnings miss, particularly if there are positive updates on clinical trials.

Supporting Evidence

Options are pricing a 17.42% move, indicating significant uncertainty that may not align with the company's potential for recovery.

The historical average reaction to earnings misses has been a positive move, suggesting that the market may overreact to negative news.

Key Risk

If clinical trial updates are more favorable than expected, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on Centessa's ability to turn around its recent earnings struggles and provide clarity on its clinical pipeline.

Bull Confirmed If

Demonstrating a significant improvement in clinical trial results or achieving an EPS that exceeds expectations would confirm the bull case.

Bear Confirmed If

Another earnings miss or negative updates on clinical trials would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move of approximately 17.42%, indicating heightened uncertainty around the earnings report.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential average move of +0.04%, which could confirm a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions, reflecting ongoing investor caution.

Miss

Should the company miss expectations again, history suggests an average move of +8.63%, likely leading to further declines in investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials.
2Management's strategy for addressing recent earnings misses.
3Any changes to financial guidance or cost management plans.
4Insights into market opportunities and competitive positioning.
5Details on upcoming product launches or partnerships.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of a company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales, which is vital for sustaining operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CNTA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q1-2026, Centessa reported an EPS of -$0.52, which was worse than the expected -$0.38, resulting in a 36.84% negative surprise. The stock reacted with a slight decline of 0.08% the following day.

Management Promises & Guidance

Focus on advancing key clinical programs.
Commitment to managing costs effectively.
Plans to provide more transparency on future revenue expectations.

Expectations

Wall Street Expectations

Bull Case

If Centessa can demonstrate significant advancements in its clinical trials and better-than-expected EPS, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company reports another earnings miss or provides disappointing updates on clinical trials, it could further erode investor confidence and lead to a negative stock reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on ongoing clinical trials?

Investors will closely watch for any progress or setbacks in clinical trials, as these can significantly influence the company's future prospects.

How does management plan to address the recent earnings misses?

Understanding management's strategy to improve financial performance is crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa to recover from its recent earnings miss, particularly if there are positive updates on clinical trials.

Supporting Evidence

Options are pricing a 17.42% move, indicating significant uncertainty that may not align with the company's potential for recovery.

The historical average reaction to earnings misses has been a positive move, suggesting that the market may overreact to negative news.

Key Risk

If clinical trial updates are more favorable than expected, it could significantly alter the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on Centessa's ability to turn around its recent earnings struggles and provide clarity on its clinical pipeline.

Bull Confirmed If

Demonstrating a significant improvement in clinical trial results or achieving an EPS that exceeds expectations would confirm the bull case.

Bear Confirmed If

Another earnings miss or negative updates on clinical trials would validate the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.42%

Historical Avg

±8.2%

Pricing rich

The options market is pricing in a significant move of approximately 17.42%, indicating heightened uncertainty around the earnings report.

Options are pricing ±17.4% while CNTA has averaged ±8.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.2%

30d HV

2.5%

Calls (5K)P/C Ratio: 27.83Puts (3K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential average move of +0.04%, which could confirm a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions, reflecting ongoing investor caution.

Miss

Should the company miss expectations again, history suggests an average move of +8.63%, likely leading to further declines in investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of key clinical trials.
2Management's strategy for addressing recent earnings misses.
3Any changes to financial guidance or cost management plans.
4Insights into market opportunities and competitive positioning.
5Details on upcoming product launches or partnerships.